乌司他丁治疗与脓毒症患者脓毒症相关性脑病风险降低相关:一项多中心观察性研究
本研究采用双队列设计,纳入多中心回顾性队列2200例脓毒症患者及单中心前瞻性验证队列534例患者,评估乌司他丁治疗与SAE发生率的关联。回顾性队列中,单因素分析(OR 0.618,95%CI 0.472-0.811,P=0.001)和多因素分析(OR 0.603,95%CI 0.453-0.802,P<0.001)均显示乌司他丁与SAE风险降低显著相关,倾向性评分匹配证实该保护关系;前瞻性验证队列同样显示乌司他丁治疗与较低SAE发生率独立相关(校正OR 0.491,95%CI 0.302-0.800,P=0.004)。单独生物标志物(一氧化氮、空腹血糖/高密度脂蛋白胆固醇比值、序贯器官衰竭评估评分、乳酸)预测价值有限(AUC均<0.70),但联合应用显著提高SAE预测准确性,最大AUC为0.726。
要点
- 多中心回顾性队列(2200例)中,乌司他丁治疗与SAE风险降低独立相关(多因素OR 0.603,95%CI 0.453-0.802,P<0.001)。
- 单中心前瞻性验证队列(534例)中,乌司他丁治疗与较低SAE发生率独立相关(校正OR 0.491,95%CI 0.302-0.800,P=0.004)。
- 单独一氧化氮、空腹血糖/高密度脂蛋白胆固醇比值、SOFA评分、乳酸对SAE预测价值有限(AUC均<0.70)。
- 上述生物标志物联合应用可提高SAE预测准确性,最大AUC为0.726。
适用人群与场景
- 脓毒症患者,来自多中心回顾性队列(2200例)及单中心前瞻性验证队列(534例)。
研究设计与关键结果
- 研究设计为双队列设计:多中心回顾性队列2200例脓毒症患者,单中心前瞻性验证队列534例患者。
- 回顾性队列单因素分析显示乌司他丁治疗与SAE风险降低相关(OR 0.618,95%CI 0.472-0.811,P=0.001)。
- 回顾性队列多因素分析显示乌司他丁治疗与SAE风险降低独立相关(OR 0.603,95%CI 0.453-0.802,P<0.001)。
- 倾向性评分匹配证实乌司他丁治疗与SAE风险降低的保护关系。
- 前瞻性验证队列显示乌司他丁治疗与较低SAE发生率独立相关(校正OR 0.491,95%CI 0.302-0.800,P=0.004)。
- 单独生物标志物(一氧化氮、空腹血糖/高密度脂蛋白胆固醇比值、SOFA评分、乳酸)预测SAE价值有限,AUC均<0.70。
- 联合生物标志物显著提高SAE预测准确性,最大AUC为0.726。
证据类型、等级与局限
- 证据类型:多中心回顾性队列研究加单中心前瞻性验证队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为乌司他丁治疗与脓毒症患者SAE发生率降低显著相关,为预防SAE和改善神经功能结局提供了新见解和潜在治疗策略。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Ulinastatin, widely used in Asia for sepsis management, lacks a comprehensive evaluation regarding its efficacy in preventing sepsis-associated encephalopathy (SAE). This study investigates ulinastatin's association with SAE incidence and explores combined biomarkers for early SAE prediction.
METHODS: This study employed a dual-cohort design involving 2,200 sepsis patients from a multicenter retrospective cohort and an independent validation cohort of 534 patients from a single-center prospective study. Using logistic regression and propensity score matching, we assessed the association between ulinastatin treatment and SAE incidence in the retrospective cohort. The findings were subsequently validated in the prospective cohort. We also evaluated clinical outcomes in ulinastatin-treated patients and examined the predictive utility of combining nitric oxide levels with key clinical indicators-including fasting blood glucose/high-density lipoprotein cholesterol ratio, Sequential Organ Failure Assessment score, and lactate levels-for early SAE risk stratification.
RESULTS: In the retrospective cohort, both univariate (odds ratio [OR] 0.618, 95% confidence interval [CI] 0.472-0.811; P = 0.001) and multivariate analyses (OR 0.603, 95% CI 0.453-0.802; P < 0.001) demonstrated that ulinastatin administration was significantly associated with reduced SAE risk. Propensity score matching confirmed this protective relationship. The prospective validation cohort similarly showed ulinastatin treatment was independently associated with lower SAE incidence (adjusted OR 0.491; 95% CI 0.302-0.800; P = 0.004). While individual biomarkers (nitric oxide, fasting blood glucose/high-density lipoprotein cholesterol, Sequential Organ Failure Assessment, and lactate) showed limited predictive value (all area under the receiver operating characteristic curves <0.70), their combination significantly improved SAE prediction accuracy, achieving a maximum area under the receiver operating characteristic curve of 0.726.
CONCLUSIONS: Ulinastatin treatment is significantly associated with reduced SAE incidence in sepsis patients, offering novel insights and potential therapeutic strategies for preventing SAE and improving neurological outcomes.
参考来源
- Xu T, Zhang Q, Ruan H, et al. Ulinastatin Treatment Associated with Lower Sepsis-Associated Encephalopathy Risk in Sepsis Patients: A Multicenter Observational Study. Shock. 2025. PMID: 42376927. doi:10.1097/SHK.0000000000002751
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。